Daiichi Sankyo, Inc. (DSI), headquartered in Parsippany, NJ, is the U.S. subsidiary of Daiichi Sankyo Co., Ltd., a global pharmaceutical company. The company is focused on the development of cardiovascular and oncology therapies and concentrates in the therapy areas of hypertension, thrombosis, dyslipidemia, diabetes and acute coronary syndrome. www.dsi.com